Home

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Search form

Recent News

Aug 07, 2017
GW Pharmaceuticals plc Reports Fiscal Third Quarter 2017 Financial Results and Operational Progress
- Epidiolex® NDA submission process underway – - Conference call today at 4:30 p.m. EST -
Read more...
Jul 24, 2017
GW Pharmaceuticals to Report Q3 Financial Results and Host Conference Call on 7 August, 2017
London, UK,  24 July 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 7 August, 2017 its third quarter financial results for the period ending 30 June, 2017.
Read more...
Jun 07, 2017
GW Pharmaceuticals to Present at the Goldman Sachs 38th Annual Global Healthcare Conference on 14 June
London, UK, 7 June 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that GW management will present at the Goldman Sachs 38th Annual Global Healthcare Conference on Wednesday, 14 June at 11:20
Read more...
View More

Pharmaceutical Development Pipeline

Pharmaceutical Development Pipeline

  • Unpartnered
  • Partnered
  • Pre-Clinic
  • Phase 1
  • Phase 2
  • Phase 3
  • Submit
  • Approved

Epidiolex

Epidiolex
Dravet Syndrome
Completed Phase 3
Epidiolex
Lennox-Gastaut Syndrome
Completed Phase 3
Epidiolex
Tuberous Sclerosis
Phase 3
Epidiolex
Infantile Spasms
Phase 2

CBDV (GWP42006)

GWP42006 (CBDV)
Epilepsy
Phase 2
GWP42006 (CBDV)
Autism Spectrum Disorders
Phase 1

Other

GWP42003 (IV)
Neonatal Hypoxic-ischemic Encephalopathy
Phase 1
GWP42002 / GWP42003
Glioma
Completed Phase 2
GWP42003
Schizophrenia
Completed Phase 2

Sativex (Partnered)

Sativex
Ms Spasticity
Approved
Learn More